1. How Should We Manage Patients with "Platinum-Sensitive" Recurrent Ovarian Cancer?
- Author
-
Ledermann, Jonathan A. and Wheeler, Sarah
- Subjects
- *
OVARIAN cancer , *CANCER patients , *THERAPEUTICS , *PACLITAXEL , *CANCER treatment , *DRUG therapy - Abstract
Decisions about the treatment of recurrent ovarian cancer are usually based on the treatment-free interval. Patients relapsing with an interval of more than six months are usually retreated with platinum-based chemotherapy. Non platinum drugs (such as paclitaxel, gemcitabine, liposomal doxorubicin or topotecan) are also active in relapsed disease. A high response rate is consistently seen with combinations of platinum and these drugs in phase II trials. ICON 4, the first large-scale randomised trial in `platinum-sensitive' relapsed ovarian cancer demonstrated a survival benefit for using platinum-based therapy in combination with paclitaxel. More studies are needed to explore other combinations of treatment in this group of women as the choice and timing of second-line therapy needs to take account of the benefits and toxicity of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF